Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma

  1. Eric C. Holland1
  1. 1Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA;
  2. 2Department of Pathology, Division of Neuropathology, University of Washington, Seattle, Washington 98104, USA;
  3. 3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts 02215, USA;
  4. 4Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts 02115, USA;
  5. 5Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts 02138, USA;
  6. 6Department of Neurology, University Hospital Zurich, Zurich 8091, Switzerland;
  7. 7Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA;
  8. 8Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo 104-0045, Japan;
  9. 9Department of Biomedical Informatics, Columbia University, New York, New York 10027, USA;
  10. 10Department of Systems Biology, Columbia University, New York, New York 10027, USA;
  11. 11Division of Shared Resources, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA;
  12. 12Human Oncology and Pathogenesis Program, Sloan Kettering Institute, New York, New York 10065, USA;
  13. 13The Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA;
  14. 14The Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts 02215, USA;
  15. 15The Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA
  1. Corresponding author: eholland{at}fredhutch.org
  1. 17 These authors contributed equally to this work.

  • 16 Present address: Division of Life Science and Department of Chemical and Biological Engineering, the Hong Kong University of Science and Technology, Clear Water Bay 999077, Hong Kong.

Abstract

Glioblastoma is the most frequently occurring and invariably fatal primary brain tumor in adults. The vast majority of glioblastomas is characterized by chromosomal copy number alterations, including gain of whole chromosome 7 and loss of whole chromosome 10. Gain of whole chromosome 7 is an early event in gliomagenesis that occurs in proneural-like precursor cells, which give rise to all isocitrate dehydrogenase (IDH) wild-type glioblastoma transcriptional subtypes. Platelet-derived growth factor A (PDGFA) is one gene on chromosome 7 known to drive gliomagenesis, but, given its location near the end of 7p, there are likely several other genes located along chromosome 7 that select for its increased whole-chromosome copy number within glioblastoma cells. To identify other potential genes that could select for gain of whole chromosome 7, we developed an unbiased bioinformatics approach that identified homeobox A5 (HOXA5) as a gene whose expression correlated with gain of chromosome 7 and a more aggressive phenotype of the resulting glioma. High expression of HOXA5 in glioblastoma was associated with a proneural gene expression pattern and decreased overall survival in both human proneural and PDGF-driven mouse glioblastoma. Furthermore, HOXA5 overexpression promoted cellular proliferation and potentiated radioresistance. We also found enrichment of HOXA5 expression in recurrent human and mouse glioblastoma at first recurrence after radiotherapy. Overall, this study implicates HOXA5 as a chromosome 7-associated gene-level locus that promotes selection for gain of whole chromosome 7 and an aggressive phenotype in glioblastoma.

Keywords

Footnotes

  • Received January 22, 2018.
  • Accepted March 13, 2018.

This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

| Table of Contents

Life Science Alliance